Recurrent Prostate Cancer after Radical Prostatectomy

Version	Summary	Created by	Modification	Content Size	Created at	Operation
1		Naeim Nabian	--	3165	2022-12-29 21:44:44	\|
2	update references and layout	Rita Xu	-21 word(s)	3144	2022-12-30 04:24:05	\|

This entry is adapted from the peer-reviewed paper 10.3390/biomedicines11010038

The main prostate cancer (PCa) treatments include surgery or radiotherapy (with or without ADT). None of the suggested treatments eliminates the risk of lymph node metastases. Conventional imaging methods, including MRI and CT scanning, are not sensitive enough for the diagnosis of lymph node metastases; the novel imaging method, PSMA PET/CT scanning, has provided valuable information about the pelvic LN involvement in patients with recurrent PCa (RPCa) after radical prostatectomy.

prostatic neoplasms recurrence lymph nodes PSMA PET/CT

1. Development of PSMA PET/CT Scan

The conventional imaging methods, such as magnetic resonance imaging (MRI) and computed tomography (CT) scanning, have limited diagnostic accuracy for lymph node (LN) involvement in patients with prostate cancer (PCa) since such methods are dependent on size and basic morphological criteria for the diagnosis of LN involvement ^[1]. Accordingly, pelvic lymph node dissection (LND) is considered the gold standard in LN staging. However, not all patients are candidates for or elect to undergo operative management. Moreover, surgery is also associated with a dramatic risk of complications, considering the relatively old age of the affected patients ^[2]^[3]; hence, an accurate noninvasive imaging technique is required to overcome these limitations.

Over the past few years, the development of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has transformed the diagnosis and management of PCa. This revolution goes back to 1996, when N-Acetylated alpha-linked acidic dipeptidase was introduced as a high-affinity agent that was primarily used for the treatment of neurologic disorders ^[4] and was further used for PET imaging of the brain to study glutamatergic transmission ^[5]. In the following years, carbon-11 (¹¹C)-choline, fluorine-18 (¹⁸F)-fluoricholine, C-acetate, fluciclovine, gallium-68 (⁶⁸Ga), and F-radiolabeled chemicals were introduced as PET scan agents and gained popularity for a short period worldwide. This was because of their advantage in directly imaging cancer, rather than the surrounding bone, compared to bone-directed PET agents ^[6]^[7]^[8]. Although the diagnostic accuracy of these PET agents in the diagnosis of prostate cancer has been confirmed, variable sensitivity and specificity values have been reported regarding patient-related, cancer-related, and treatment-related factors ^[8]. In a comparison of the diagnostic accuracy of the two agents approved in the United States, C-choline and fluciclovine, the latter appeared to detect more local, nodal, and bony diseases with a higher sensitivity (37% vs. 32%) and specificity (67% vs. 40%) ^[9].

The first practical human PSMA PET agent, ¹⁸F-DCFBC, was developed in 2008. This type II transmembrane protein, in human zinc-containing metalloenzyme with glutamate carboxypeptidase/folate hydrolase activity, is expressed in the apical side of the prostatic ducts and is upregulated by PCa cells. The binding of the PSMA ligand to its anchored cell membrane target mediates internalization through clathrin-dependent endocytosis, thereby enhancing the retention of conjugated radionuclides into the cells, even in small-volume sites ^[10]^[11]. The first radiometalated PSMA agent, technetium-99m, a labeled inhibitor of PSMA, was developed in 2008 ^[12], and later in 2010, the first ⁶⁸Ga-labeled PSMA inhibitor was synthesized as the first clinical agent for PSMA PET imaging, which gained popularity due to its high diagnostic accuracy. It can detect as many as 50% of patients with low serum levels of prostate-specific antigen (PSA < 0.5 ng/mL) and 60% of patients with moderate levels (0.5–1 ng/mL) ^[9]. Moreover, it can detect additional diseases that are not detected by choline imaging ^[13].

Researchers have developed several chelators for ⁶⁸Ga PSMA, including the HBED-CC chelators, known as PSMA-11 ^[14] and ¹⁸F-DCFPyl ^[15], which have been widely used in recent years, especially in Europe and the USA ^[16]. The high levels of radiotracer excretion and urinary bladder activity result in uptake in other sites other than the prostate, including the salivary glands and lacrimal glands, kidneys and liver, spleen, small intestine, and urinary collecting system, which could mask small local recurrences in this vicinity or be misdiagnosed as metastasis ^[11]. The targeted radionuclide chelators PSMA-617 (¹⁷⁷Lu-labeled ligand) ^[17] and ¹⁸F-PSMA-1007 were developed with less urinary excretion than ¹⁸F-DCFPyl ^[18].

Following the rapid development of PSMA PET imaging (in no longer than a decade), hundreds of cohort and clinical trials with promising results have been published annually on its diagnostic accuracy in the diagnosis and staging of the disease and metastasis in patients with primary/recurrent PCa ^[19]^[20]. Further meta-analysis studies and prospective and randomized clinical trials also confirmed the high positive and negative predictive values (PPV and NPV) of PSMA PET for PCa ^[21]^[22]^[23]^[24].

2. Nodal Irradiation in PSMA-Positive Patients

Many studies have suggested a change in the therapeutic plan of a given patient, especially considering the treatment for LN involvement, according to PSMA PET/CT scan results ^[11]^[25]^[26]; however, most studies have reported the overall rates and have not reported the patient outcomes with PSMA-positive or -negative LNs. The treatment options for patients with localized or regional LN metastases of PCa include surgery (LND) or irradiation (LNRT, with or without androgen deprivation). There is controversy related to the preference for these methods in PSMA-positive LNs in patients with the recurrence of PCa after RP.

A systematic review of 27 studies (6 of which used PSMA) showed a mean complete biochemical response in 44.3% (13–79.5%) of cases after SLND with 2- and 5-year biochemical-recurrence-free survival rates (BCRFS) of 23–64% and 6–31%, respectively ^[27]. The inconsistencies in the reported patient outcomes could be caused by differences in the type of detection method used, the type of RT (LN-specific stereotactic body RT (SBRT) or whole-pelvis radiotherapy (WPRT)), and the variation in the RT regimens and doses ^[28]. In a recent study involving 100 patients with BCR (24%) or biochemical persistence (76%), the results showed that PSMA PET/CT could detect 1, 2, 3, or more LN metastases in 35%, 23%, and 42% of the patients; the treatment of all LN cases with RT and ADT in 83% of patients showed improved BCR-free survival in these patients, thereby confirming the use of RT based on the results of a PET/CT scan ^[29]. Furthermore, another recent study showed that most patients with high PSA levels considered that a relapse of PCa could be successfully diagnosed as a recurrence by ⁶⁸Ga-PSMA (63%). This study also concluded that PSMA PET/CT scans have a high level of significance in predicting the outcomes of patients with PSA relapse ^[30].

The table below summarizes the results of studies evaluating the outcomes of patients with PSMA-positive LN, organized in chronological order (Table 1). Focuses on the PSMA PET/CT, those studies using a different diagnostic method (such as choline or FDG PET/CT, etc.) were not included. Researchers also evaluated the results of the studies addressing the patient outcomes after the diagnosis of LN by PSMA PET/CT and did not include studies reporting the results of radioguided treatment strategies using this imaging modality.

Table 1. The summary of studies reporting the treatment outcomes of PSMA-positive lymph nodes in patients with a recurrence of prostate cancer after primary treatment with radical prostatectomy.

Author, Year of Publication	Number of Patients	Imaging Method	Treatments Applied	Median Follow-Up (Months)	Conclusion
Author, Year of Publication	Number of Patients	Imaging Method	Treatments Applied	Median Follow-Up (Months)	Recurrence or Response Rate	Survival
Porres et al. ^[31], 2017	87	¹⁸FEC or ⁶⁸Ga-PSMA PET/CT	Salvage extended lymph node dissection	21	Complete biochemical response: 27.5%, Incomplete biochemical response: 40.6%	ADT-free: 62.2%, CSM: 3.7%, 3-year BCR-free: 69.3%, systemic-therapy-free survival: 77.0%, clinical-recurrence-free survival: 75%, for patients with complete biochemical response
Henkenberenz et al. ^[32], 2017	23	⁶⁸GA-PSMA PET/CT	Salvage LNRT	12.4	Recurrence outside the initial radiation field: 12.9%	BCR-free survival: 95.6%, systemic-therapy-free survival: 100%
Fossati et al. ^[33], 2019	654	¹¹C- or ⁶⁸Ga-PSMA PET/CT	Salvage LND	30	Early clinical recurrence: 25%	CSM: 20% in patients with and 1.4% in patients without early clinical recurrence
Schmidt-Hegemann et al. ^[34], 2020	100	⁶⁸GA-PSMA PET/CT	Salvage LNRT vs. LND	17 in SLND and 31 in salvage LNRT	LND had higher distant metastases (52% vs. 21%) and secondary treatments (39% vs. 15%).	2-year BCR-free survival was 92% in salvage LNRT and 30% in SLND
Kretschmer et al. ^[35], 2021	138	⁶⁸GA-PSMA PET/CT	Salvage LNRT vs. LND	47 in SLNRT and 31 in SLND	BCR: 40.3% for SLNRT and 86.4% for SLND, distant metastasis: 31.3% for SLNRT and 36.4% for SLND	Median metastasis-free survival: 70 months for all (57.6 months for SLNRT and 39.5 months for SLND; not different)
Rogowski et al. ^[29], 2021	100	¹⁸FEC and ⁶⁸Ga-PSMA PET/CT	sENRT	37	Metastasis: 83% only pelvic, 2% only para-aortic, 15% pelvic and para-aortic LN metastases.	1, 2-, and 3-year BCR-free survival: 80.7%, 71.6%, and 65.8%, and 1, 2-, and 3-year distant-metastasis-free survival: 91.6%, 79.1%, and 66.4%, respectively

Abbreviations: BCR, biochemical recurrence; ADT, androgen deprivation therapy; CSM, cancer-specific mortality; RP, radical prostatectomy; LNRT, lymph node radiotherapy; PSMA PET/CT, prostate-specific membrane antigen positron emission tomography/computer tomography; LND, lymph node dissection; sENRT, salvage elective nodal radiotherapy; PSA, prostate-specific antigen.

Porres et al. investigated the outcomes of radiation in patients with BCR and PET-positive LNs (¹⁸FEC or ⁶⁸Ga-PSMA). In a seven-year study involving 87 patients, 87.4% of the cases had undergone RP, 57.9% of the patients had adjuvant/salvage RT (additionally), and 18.4% of the participants received ADT before sLND. The patients’ favorable outcomes implied that extended salvage lymph node dissection is an appropriate and safe therapy in these patients, which allows for the postponement of systemic therapy ^[31]. A study involving 23 patients with PET-positive LNs also showed that RT significantly decreased PSA levels from the median of 2.75 to 1.37 ng/mL. The researchers concluded that RT is a promising therapy for the local treatment of patients with an isolated LN metastasis of PCa ^[32]. In an extensive multi-institutional analysis of patients with BCR and PET-positive LNs (¹¹C-choline or ⁶⁸Ga-PSMA), Fossati et al. showed that the patient outcomes after salvage LND depend on the clinical recurrence rate. According to their findings, they developed a model to predict the early clinical recurrence one year after salvage LND according to the Gleason score, the time from RP to PSA rising, hormonal therapy at PSA rise after RP, retroperitoneal or three or more spots on a PET/CT scan, and the PSA level at SLND. These researchers suggested the use of this tool for appropriate patient selection ^[33]. As shown above, the existing evidence indicates that PET-positive LNs are an appropriate diagnostic tool for the definite diagnosis of PCa recurrence. Other researchers have also confirmed ⁶⁸Ga-PSMA PET/CT for the diagnosis of positive pelvic LNs in patients with BCR or high-risk primary PCa (one false-negative LN and two false-positive LNs) ^[36] (this study was not included in the table since the table only addresses studies on RPCa).

Few studies have compared the patient outcomes for different treatment modalities. Schmidt-Hegemann et al. compared the results of 67 patients who underwent salvage LNRT with 33 patients who underwent salvage LND and reported the priority of LNRT, considering the lower rates of distant metastasis (92% vs. 30%), the need for secondary treatments (5% vs. 39%), and prolonged BCRFS (HR = 4.204) ^[34]. In 2021, Kretschmer et al. compared the outcomes of 71 patients undergoing salvage LND with 67 patients undergoing salvage LNRT and reported similar MFS, general health-related quality of life, daily pad usage, and scores for the two modalities. However, the only significant difference was associated with a higher PSA-progression-free survival in the salvage LNRT group ^[35].

An important issue challenging the comparison of the rates of patient outcomes among studies is the presence of confounders, i.e., factors affecting the patient outcomes that are independent of the treatment plan or the diagnostic accuracy of the PSMA PET/CT scan. These factors include the number of positive LNs on the ⁶⁸Ga-PSMA PET/CT scan, the Gleason score, the duration of ADT before recurrence, and the duration from the initial diagnosis to relapse ^[30]^[37]. Fossati et al. have also developed a model to predict the outcome of salvage LND according to Gleason grade group 5, the time from RP to PSA rising, hormonal therapy at PSA rise after RP, retroperitoneal or three or more spots on a PET/CT scan, and the PSA level at SLND ^[33].

Interestingly, Farolfi et al. compared the results of ⁶⁸Ga-PSMA PET/CT before and after salvage LND in 16 patients with persistent BCR and determined the recurrence after LND in 25% of cases (n = 4) and repeated local therapy after salvage LND in 9 patients (7 with RT and 2 with surgery). They also reported that all regions detected by PET as positive were truly positive ^[38]. These findings suggest that the selected MDT was not a complete treatment. Considering the high mortality rate in patients with failed salvage therapy (above 60%) ^[39], it is important to select an appropriate treatment method to reduce the risk of failed treatment and recurrence after the treatment of LN metastasis ^[40]. De Bari et al. suggested that adopting larger target volumes treated at least 95% of lymph node regions with the risk of occult relapse ^[41]. It was also suggested to estimate the oncologic benefit of MDT and select the most appropriate treatment strategy regarding patients’ conditions when this imaging tool was used for treatment decisions in LN-positive patients ^[33].

By the accumulation of the above data, in one of the most important ongoing trials the investigators are testing the benefit of treating PET- and/or MRI-defined involved nodes by IMRT or SBRT along with the elective treatment of the pelvic nodes and the prostatic bed in the salvage settings ^[42].

3. Nodal Irradiation in PSMA-Negative Patients

In the recently published SPPORT study, the elective treatment of the pelvic nodes in the pre-PSMA era has been associated with superior BCRFS compared to treatment of prostate bed alone in the salvage setting ^[43]. However, the treatment and/or outcome of patients diagnosed as LN-negative using a PSMA PET/CT scan has mainly been reported in the subgroup analyses of studies and scarcely as their main objective. Most studies have indicated that patients with PSMA-negative LNs had a lower PSA compared to those with PSMA-positive LNs ^[44], suggesting that they have a better prognosis (1- and 2-year BCRFS rates of 87% and 76%, respectively) ^[45]. Comparing the results of histological metastasis, as determined by LND, with the results of PSMA PET also showed that the consideration of a negative 68Ga-PSMA PET/CT as the basis of not performing pelvic LND can avoid unnecessary LND treatments in 80% of patients ^[46]. However, the specificity of PSMA PET/CT in predicting pathologically confirmed positive nodes ranged from 87.5 to 97.3%, and only 24% of patients diagnosed as negative by PSMA were found to be positive histologically ^[27]. Comparing the histological reports with the PSMA PET results in patients before salvage LND showed specificity values of 74.1% in the side-based analysis and 87.5% in the LN field-based analysis and an NPV of 90.9% in the LN field-based analysis ^[47]. Nonetheless, the majority of studies have not reported the NPV of PSMA PET/CT in patients with RPCa ^[22]^[48], in which has been reported in patients with primary PCa ^[49]^[50].

As discussed earlier, small LNs cannot be captured by PET scans, and comparing the results of 68Ga-PSMA PET/CT or PET/MRI with histopathologic results showed a median diameter of 3.4 mm (IQR 2.1–5.4 mm) for metastatic LNs that were considered negative on a ⁶⁸Ga-PSMA PET/CT scan ^[51]. Furthermore, although the recurrence rate of PSMA-negative patients is lower than those with positive PSMA (16.7% vs. 50%, respectively) ^[52], some have reported similar BCRFS rates between PSMA-negative and -positive patients (82% vs. 74%, respectively) ^[53]. Accordingly, the BCR rate in PSMA-negative patients should be considered. A follow-up of 103 patients with BCR and negative PSMA LNs who were receiving no treatment detected clinical recurrence in the prostatic fossa (45.6%), nodes (38.6%), and bone (15.8%) at a median of 15.4 months, with overall clinical-recurrence-free survival rates of 61.4% after one year and 34.8% after two years, which was longer in patients with a lower ISUP grade group ^[54]. These findings support the necessity of active surveillance for these patients using on-time and appropriate therapeutic strategies. However, leaving these patients without treatment may be a great risk; some suggest salvage LNRT, even in the absence of PSMA-diagnosed LNs, considering the low sensitivity of PSMA PET/CT in diagnosing micrometastases ^[55]^[56]. The Table 2 summarizes the results of studies reporting the outcomes of PSMA-negative LNs in patients suspected of BCR.

Table 2. The summary of studies reporting the treatment outcomes of patients with PSMA-negative results for prostate bed and lymph node metastasis in patients with the biochemical recurrence of prostate cancer (referred for treatment) after radical prostatectomy.

Author, Year of Publication	Ratio of Patients with Negative PSMA PET/CT to All Patients	Treatments Applied	Median Duration of Follow-up (Months)	Conclusion
Zschaek et al. ^[57], 2017	Not mentioned	Salvage LNRT	29	Median PSA response:9% decline for PSMA-negative patients and pathological N+ vs. 79% decline for PSMA negative and pathological N0
Emmett et al. ^[58], 2017	60/164	Salvage LNRT and prostate bed RT	10.5	In total, 85% with negative PSMA responded to treatment, and PSA increased in 65% of untreated patients.
Schmidt-Hegemann et al. ^[53], 2019	48/90	Salvage LNRT and/or ADT	23	Similar recurrence-free rates between positive and negative PSMA (74% vs. 82%)
Emmett et al. ^[59], 2020	90/260	Salvage LNRT and prostate bed RT		Negative PSMA plus salvage LNRT was the best predictor of 3-year free-from-progression rate (82.5%), and 66% of untreated patients had a PSA increase.

Abbreviations: PSMA, prostate-specific membrane antigen; LNRT, lymph node radiotherapy; PSA, prostate-specific antigen; RP, radical prostatectomy. Note: all studies used ⁶⁸GA-prostate-specific membrane antigen positron emission tomography/computer tomography as the imaging method.

Emmet et al. focused on the predictive value of negative PSMA results for LN metastasis in patients with persistent PSA (with PSA readings between 0.05 and 1.0 ng/mL). In their first study (2017) among 60 patients with a negative PSMA result, 27 patients underwent SRT (45%), and the others did not; among those not receiving treatment, 65% had increased PSA levels. They also showed a high response to treatment in PSMA-negative patients, highlighting the value of treatment in these patients ^[58]. In 2021, they published the results of a three-year follow-up of 260 patients. In their study, 32% of PSMA-negative patients did not receive treatment, and 66% showed PSA progression (with a mean rise of 1.59 ng/mL over three years). They also reported the higher likelihood of salvage LNRT and ADT in PSMA-positive patients compared to PSMA-negative patients ^[59]. Zschaek et al. evaluated patients with extremely high risk PCa who underwent PSMA PET before salvage LNRT and showed that treatment with salvage LNRT significantly prevented PSA increase in patients with negative PSMA LNs ^[57]. Schmidt-Hegemann et al. evaluated 204 consecutive patients that were referred for salvage LNRT and underwent PSMA PET before treatment; about half of their study population had negative PET results, 81% of whom also had a low PSA level (≤0.5 ng/mL). None of the patients with a negative PET result underwent LNRT or other treatments (only one continued ADT). However, the results showed that the PSMA results (positive or negative) did not influence the outcome (BFRS), which was mainly due to the advantage of treatment intensification in patients with positive PSMA PET results ^[53]. A review of 27 studies (n = 2832 patients with a primary diagnosis of PCa) also confirmed that the patient risk score should be considered for the decision of pelvic LND, even in patients with negative PSMA PET/CT results ^[60]. Other studies have also concluded that a negative PSMA PET/CT result does not rule out LN metastasis ^[61]^[62]. Accordingly, it is speculated that a risk scoring system should be used for making decisions about the treatment of PSMA-negative patients in cases with BCR of PCa. However, such results have not been confirmed for these patients. Kiste et al. reported their results in their cohort based on PSMA-negative PET results and showed that the initial T status, the M status at recurrence, the PSA level at the time of salvage LNRT, additive ADR, and elective prostate bed RT could significantly predict the BCRFS during a median follow-up of 28 months ^[63]. Further studies are required to determine the most appropriate type of RT, the extent of irradiation in patients with BCR of PCa, and no evidence of LN metastasis on a PSMA PET/CT scan.

References

Hövels, A.; Heesakkers, R.; Adang, E.; Jager, G.; Strum, S.; Hoogeveen, Y.; Severens, J.; Barentsz, J. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: A meta-analysis. Clin. Radiol. 2008, 63, 387–395.
Cheung, D.C.; Fleshner, N.; Sengupta, S.; Woon, D. A narrative review of pelvic lymph node dissection in prostate cancer. Transl. Androl. Urol. 2020, 9, 3049.
Fossati, N.; Willemse, P.-P.M.; Van den Broeck, T.; van den Bergh, R.C.; Yuan, C.Y.; Briers, E.; Bellmunt, J.; Bolla, M.; Cornford, P.; De Santis, M. The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: A systematic review. Eur. Urol. 2017, 72, 84–109.
Jackson, P.F.; Cole, D.C.; Slusher, B.S.; Stetz, S.L.; Ross, L.E.; Donzanti, B.A.; Trainor, D.A. Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated α-linked acidic dipeptidase. J. Med. Chem. 1996, 39, 619–622.
Carter, R.E.; Feldman, A.R.; Coyle, J.T. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc. Natl. Acad. Sci. USA 1996, 93, 749–753.
Linxweiler, J.; Saar, M.; Al-Kailani, Z.; Janssen, M.; Ezziddin, S.; Stöckle, M.; Siemer, S.; Ohlmann, C.-H. Robotic salvage lymph node dissection for nodal-only recurrences after radical prostatectomy: Perioperative and early oncological outcomes. Surg. Oncol. 2018, 27, 138–145.
Herlemann, A.; Kretschmer, A.; Buchner, A.; Karl, A.; Tritschler, S.; El-Malazi, L.; Fendler, W.P.; Wenter, V.; Ilhan, H.; Bartenstein, P. Salvage lymph node dissection after 68Ga-PSMA or 18F-FEC PET/CT for nodal recurrence in prostate cancer patients. Oncotarget 2017, 8, 84180.
Brogsitter, C.; Zöphel, K.; Kotzerke, J. 18F-Choline, 11C-choline and 11C-acetate PET/CT: Comparative analysis for imaging prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging 2013, 40, 18–27.
Nanni, C.; Zanoni, L.; Pultrone, C.; Schiavina, R.; Brunocilla, E.; Lodi, F.; Malizia, C.; Ferrari, M.; Rigatti, P.; Fonti, C. 18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: Results of a prospective trial. Eur. J. Nucl. Med. Mol. Imaging 2016, 43, 1601–1610.
Foss, C.A.; Mease, R.C.; Cho, S.Y.; Kim, H.J.; Pomper, M.G. GCPII imaging and cancer. Curr. Med. Chem. 2012, 19, 1346–1359.
Sheikhbahaei, S.; Afshar-Oromieh, A.; Eiber, M.; Solnes, L.B.; Javadi, M.S.; Ross, A.E.; Pienta, K.J.; Allaf, M.E.; Haberkorn, U.; Pomper, M.G. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 2117–2136.
Banerjee, S.R.; Foss, C.A.; Castanares, M.; Mease, R.C.; Byun, Y.; Fox, J.J.; Hilton, J.; Lupold, S.E.; Kozikowski, A.P.; Pomper, M.G. Synthesis and evaluation of technetium-99m-and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J. Med. Chem. 2008, 51, 4504–4517.
Bluemel, C.; Krebs, M.; Polat, B.; Linke, F.; Eiber, M.; Samnick, S.; Lapa, C.; Lassmann, M.; Riedmiller, H.; Czernin, J. 68Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18F-choline-PET/CT. Clin. Nucl. Med. 2016, 41, 515.
Eder, M.; Schäfer, M.; Bauder-Wüst, U.; Hull, W.-E.; Wängler, C.; Mier, W.; Haberkorn, U.; Eisenhut, M. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug. Chem. 2012, 23, 688–697.
Chen, Y.; Pullambhatla, M.; Foss, C.A.; Byun, Y.; Nimmagadda, S.; Senthamizhchelvan, S.; Sgouros, G.; Mease, R.C.; Pomper, M.G. 2-(3--ureido)-pentanedioic acid, DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin. Cancer Res. 2011, 17, 7645–7653.
Morigi, J.J.; Stricker, P.D.; van Leeuwen, P.J.; Tang, R.; Ho, B.; Nguyen, Q.; Hruby, G.; Fogarty, G.; Jagavkar, R.; Kneebone, A. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J. Nucl. Med. 2015, 56, 1185–1190.
Afshar-Oromieh, A.; Hetzheim, H.; Kratochwil, C.; Benesova, M.; Eder, M.; Neels, O.C.; Eisenhut, M.; Kübler, W.; Holland-Letz, T.; Giesel, F.L. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: Biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J. Nucl. Med. 2015, 56, 1697–1705.
Giesel, F.L.; Hadaschik, B.; Cardinale, J.; Radtke, J.; Vinsensia, M.; Lehnert, W.; Kesch, C.; Tolstov, Y.; Singer, S.; Grabe, N. F-18 labelled PSMA-1007: Biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 678–688.
Choyke, P.L.; Bouchelouche, K. Prostate specific membrane antigen (PSMA) imaging: The past is prologue. Transl. Androl. Urol. 2019, 8, 283.
Murphy, D.G.; Sweeney, C.J.; Tombal, B. “ Gotta Catch’em All”, or Do We? Pokemet Approach to Metastatic Prostate Cancer. Eur. Urol. 2017, 72, 1–3.
Hope, T.A.; Afshar-Oromieh, A.; Eiber, M.; Emmett, L.; Fendler, W.P.; Lawhn-Heath, C.; Rowe, S.P. Imaging prostate cancer with PSMA PET/CT and PET/MRI: Current and future applications. AJR. Am. J. Roentgenol. 2018, 211, 286.
Fendler, W.P.; Calais, J.; Eiber, M.; Flavell, R.R.; Mishoe, A.; Feng, F.Y.; Nguyen, H.G.; Reiter, R.E.; Rettig, M.B.; Okamoto, S. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: A prospective single-arm clinical trial. JAMA Oncol. 2019, 5, 856–863.
Perera, M.; Papa, N.; Christidis, D.; Wetherell, D.; Hofman, M.S.; Murphy, D.G.; Bolton, D.; Lawrentschuk, N. Sensitivity, specificity, and predictors of positive 68Ga–prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: A systematic review and meta-analysis. Eur. Urol. 2016, 70, 926–937.
Rahman, L.A.; Rutagengwa, D.; Lin, P.; Lin, M.; Yap, J.; Lai, K.; Mancuso, P.; Rathore, P.; Haghighi, K.; Gassner, P. High negative predictive value of 68Ga PSMA PET-CT for local lymph node metastases in high risk primary prostate cancer with histopathological correlation. Cancer Imaging 2019, 19, 86.
Roach, P.J.; Francis, R.; Emmett, L.; Hsiao, E.; Kneebone, A.; Hruby, G.; Eade, T.; Nguyen, Q.A.; Thompson, B.D.; Cusick, T. The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: Results of an Australian prospective multicenter study. J. Nucl. Med. 2018, 59, 82–88.
Sterzing, F.; Kratochwil, C.; Fiedler, H.; Katayama, S.; Habl, G.; Kopka, K.; Afshar-Oromieh, A.; Debus, J.; Haberkorn, U.; Giesel, F.L. 68 Ga-PSMA-11 PET/CT: A new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging 2016, 43, 34–41.
Ploussard, G.; Gandaglia, G.; Borgmann, H.; De Visschere, P.; Heidegger, I.; Kretschmer, A.; Mathieu, R.; Surcel, C.; Tilki, D.; Tsaur, I. Salvage lymph node dissection for nodal recurrent prostate cancer: A systematic review. Eur. Urol. 2019, 76, 493–504.
De Bleser, E.; Tran, P.T.; Ost, P. Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer. Curr. Opin. Urol. 2017, 27, 587–595.
Rogowski, P.; Trapp, C.; von Bestenbostel, R.; Eze, C.; Ganswindt, U.; Li, M.; Unterrainer, M.; Zacherl, M.J.; Ilhan, H.; Beyer, L. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy. Eur. J. Nucl. Med. Mol. Imaging 2021, 49, 1417–1428.
Von Eyben, F.E.; Soydal, C.; von Eyben, R. 68Ga-PSMA PET/CT for Patients with PSA Relapse after Radical Prostatectomy or External Beam Radiotherapy. Diagnostics 2021, 11, 622.
Porres, D.; Pfister, D.; Thissen, A.; Kuru, T.; Zugor, V.; Buettner, R.; Knuechel, R.; Verburg, F.; Heidenreich, A. The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer. Prostate Cancer Prostatic Dis. 2017, 20, 85–92.
Henkenberens, C.; Von Klot, C.A.; Ross, T.L.; Bengel, F.M.; Wester, H.-J.; HÜPER, K.; Christiansen, H.; Derlin, T. 68Ga-PSMA ligand PET/CT-based radiotherapy for lymph node relapse of prostate cancer after primary therapy delays initiation of systemic therapy. Anticancer Res. 2017, 37, 1273–1279.
Fossati, N.; Suardi, N.; Gandaglia, G.; Bravi, C.A.; Soligo, M.; Karnes, R.J.; Shariat, S.; Battaglia, A.; Everaerts, W.; Joniau, S. Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: Results from a large, multi-institutional analysis. Eur. Urol. 2019, 75, 176–183.
Schmidt-Hegemann, N.-S.; Buchner, A.; Eze, C.; Rogowski, P.; Schaefer, C.; Ilhan, H.; Li, M.; Fendler, W.P.; Bartenstein, P.; Ganswindt, U. PSMA-positive nodal recurrence in prostate cancer: Salvage radiotherapy is superior to salvage lymph node dissection in retrospective analysis. Strahlenther. Und Onkol. 2020, 196, 637.
Kretschmer, A.; Milow, J.; Eze, C.; Buchner, A.; Li, M.; Westhofen, T.; Fuchs, F.; Rogowski, P.; Trapp, C.; Ganswindt, U. Patient-Reported and Oncological Outcomes of Salvage Therapies for PSMA-Positive Nodal Recurrent Prostate Cancer: Real-Life Experiences and Implications for Future Trial Design. Front. Oncol. 2021, 11, 2408.
Hijazi, S.; Meller, B.; Leitsmann, C.; Strauss, A.; Meller, J.; Ritter, C.; Lotz, J.; Schildhaus, H.U.; Trojan, L.; Sahlmann, C. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography. Prostate 2015, 75, 1934–1940.
Pereira Mestre, R.; Treglia, G.; Ferrari, M.; Pascale, M.; Mazzara, C.; Azinwi, N.C.; Llado’, A.; Stathis, A.; Giovanella, L.; Roggero, E. Correlation between PSA kinetics and PSMA-PET in prostate cancer restaging: A meta-analysis. Eur. J. Clin. Investig. 2019, 49, e13063.
Farolfi, A.; Ilhan, H.; Gafita, A.; Calais, J.; Barbato, F.; Weber, M.; Afshar-Oromieh, A.; Spohn, F.; Wetter, A.; Rischpler, C. Mapping prostate cancer lesions before and after unsuccessful salvage lymph node dissection using repeat PSMA PET. J. Nucl. Med. 2020, 61, 1037–1042.
Bravi, C.A.; Fossati, N.; Gandaglia, G.; Suardi, N.; Mazzone, E.; Robesti, D.; Osmonov, D.; Juenemann, K.-P.; Boeri, L.; Karnes, R.J. Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: Not as good as previously thought. Eur. Urol. 2020, 78, 661–669.
Bravi, C.A.; Fossati, N.; Gandaglia, G.; Suardi, N.; Mazzone, E.; Robesti, D.; Osmonov, D.; Juenemann, K.-P.; Boeri, L.; Karnes, R.J. Assessing the best surgical template at salvage pelvic lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: When can bilateral dissection be omitted? Results from a multi-institutional series. Eur. Urol. 2020, 78, 779–782.
De Bari, B.; Mazzola, R.; Aiello, D.; Aloi, D.; Gatta, R.; Corradini, S.; Salgarello, M.; Alongi, F. (68Ga)-PSMA-PET/CT for the detection of postoperative prostate cancer recurrence: Possible implications on treatment volumes for radiation therapy. Cancer/Radiother. 2019, 23, 194–200.
De Bruycker, A.; Spiessens, A.; Dirix, P.; Koutsouvelis, N.; Semac, I.; Liefhooghe, N.; Gomez-Iturriaga, A.; Everaerts, W.; Otte, F.; Papachristofilou, A. PEACE V–Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): A study protocol for a randomized controlled phase II trial. BMC Cancer 2020, 20, 406.
Pollack, A.; Karrison, T.G.; Balogh, A.G.; Gomella, L.G.; Low, D.A.; Bruner, D.W.; Wefel, J.S.; Martin, A.-G.; Michalski, J.M.; Angyalfi, S.J. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): An international, multicentre, randomised phase 3 trial. Lancet 2022, 399, 1886–1901.
Perry, E.; Talwar, A.; Taubman, K.; Ng, M.; Wong, L.-M.; Booth, R.; Sutherland, T.R. DCFPyL PET/CT in detection and localization of recurrent prostate cancer following prostatectomy including low PSA < 0.5 ng/mL. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 2038–2046.
Dekalo, S.; Kuten, J.; Mintz, I.; Fahoum, I.; Gitstein, G.; Keizman, D.; Sarid, D.; Matzkin, H.; Mabjeesh, N.J.; Beri, A. Preoperative 68Ga-PSMA PET/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection. Prostate Cancer Prostatic Dis. 2021, 24, 910–916.
Yaxley, J.W.; Raveenthiran, S.; Nouhaud, F.-X.; Samartunga, H.; Yaxley, A.J.; Coughlin, G.; Delahunt, B.; Egevad, L.; McEwan, L.; Wong, D. Outcomes of primary lymph node staging of intermediate and high risk prostate cancer with 68Ga-PSMA positron emission tomography/computerized tomography compared to histological correlation of pelvic lymph node pathology. J. Urol. 2019, 201, 815–820.
Mandel, P.; Tilki, D.; Chun, F.K.; Pristupa, E.; Graefen, M.; Klutmann, S.; Budäus, L.; Steuber, T. Accuracy of 68Ga-prostate-specific membrane antigen positron emission tomography for the detection of lymph node metastases before salvage lymphadenectomy. Eur. Urol. Focus 2020, 6, 71–73.
Luiting, H.B.; van Leeuwen, P.J.; Busstra, M.B.; Brabander, T.; van der Poel, H.G.; Donswijk, M.L.; Vis, A.N.; Emmett, L.; Stricker, P.D.; Roobol, M.J. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: An overview of the current literature. BJU Int. 2020, 125, 206.
Meijer, D.; de Barros, H.A.; van Leeuwen, P.J.; Bodar, Y.J.; van der Poel, H.G.; Donswijk, M.L.; Hendrikse, N.H.; van Moorselaar, R.J.A.; Nieuwenhuijzen, J.A.; Oprea-Lager, D.E. The predictive value of preoperative negative prostate specific membrane antigen positron emission tomography imaging for lymph node metastatic prostate cancer. J. Urol. 2021, 205, 1655–1662.
Amiel, T.; Würnschimmel, C.; Heck, M.; Horn, T.; Nguyen, N.; Budäus, L.; Knipper, S.; Wenzel, M.; Rauscher, I.; Eiber, M. Regional lymph node metastasis on prostate specific membrane antigen positron emission tomography correlates with decreased biochemical recurrence-free and therapy-free survival after radical prostatectomy: A retrospective single-center single-arm observational study. J. Urol. 2021, 205, 1663–1670.
Abufaraj, M.; Grubmüller, B.; Zeitlinger, M.; Kramer, G.; Seitz, C.; Haitel, A.; Baltzer, P.; Hacker, M.; Wadsak, W.; Pfaff, S. Prospective evaluation of the performance of Ga-PSMA-11 PET/CT (MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 2169–2177.
Van Leeuwen, P.J.; Donswijk, M.; Nandurkar, R.; Stricker, P.; Ho, B.; Heijmink, S.; Wit, E.M.; Tillier, C.; van Muilenkom, E.; Nguyen, Q. Gallium-68-prostate-specific membrane antigen (68Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate-and high-risk prostate cancer. BJU Int. 2019, 124, 62–68.
Schmidt-Hegemann, N.-S.; Stief, C.; Kim, T.-H.; Eze, C.; Kirste, S.; Strouthos, I.; Li, M.; Schultze-Seemann, W.; Ilhan, H.; Fendler, W.P. Outcome after PSMA PET/CT–based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: A 2-institution retrospective analysis. J. Nucl. Med. 2019, 60, 227–233.
Celli, M.; De Giorgi, U.; Caroli, P.; Di Iorio, V.; Fantini, L.; Rossetti, V.; Foca, F.; Nicolini, S.; Giganti, M.; Paganelli, G. Clinical value of negative 68 Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 87–94.
Bottke, D.; Miksch, J.; Thamm, R.; Krohn, T.; Bartkowiak, D.; Beer, M.; Bolenz, C.; Beer, A.J.; Prasad, V.; Wiegel, T. Changes of Radiation Treatment Concept Based on 68Ga-PSMA-11-PET/CT in Early PSA-Recurrences After Radical Prostatectomy. Front. Oncol. 2021, 11, 1864.
Koschel, S.; Taubman, K.; Sutherland, T.; Yap, K.; Chao, M.; Guerrieri, M.; Benson, A.; Starmans, M.; Byrne, G.; Ong, G. Patterns of disease detection using DCFPyL PET/CT imaging in patients with detectable PSA post prostatectomy being considered for salvage radiotherapy: A prospective trial. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 3712–3722.
Zschaeck, S.; Wust, P.; Beck, M.; Wlodarczyk, W.; Kaul, D.; Rogasch, J.; Budach, V.; Furth, C.; Ghadjar, P. Intermediate-term outcome after PSMA-PET guided high-dose radiotherapy of recurrent high-risk prostate cancer patients. Radiat. Oncol. 2017, 12, 140.
Emmett, L.; van Leeuwen, P.J.; Nandurkar, R.; Scheltema, M.J.; Cusick, T.; Hruby, G.; Kneebone, A.; Eade, T.; Fogarty, G.; Jagavkar, R. Treatment outcomes from 68Ga-PSMA PET/CT–informed salvage radiation treatment in men with rising PSA after radical prostatectomy: Prognostic value of a negative PSMA PET. J. Nucl. Med. 2017, 58, 1972–1976.
Emmett, L.; Tang, R.; Nandurkar, R.; Hruby, G.; Roach, P.; Watts, J.A.; Cusick, T.; Kneebone, A.; Ho, B.; Chan, L. 3-Year freedom from progression after 68Ga-PSMA PET/CT–triaged management in men with biochemical recurrence after radical prostatectomy: Results of a prospective multicenter trial. J. Nucl. Med. 2020, 61, 866–872.
Stabile, A.; Pellegrino, A.; Mazzone, E.; Cannoletta, D.; de Angelis, M.; Barletta, F.; Scuderi, S.; Cucchiara, V.; Gandaglia, G.; Raggi, D. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard. Eur. Urol. Oncol. 2021, 5, 1–17.
Hope, T.A.; Eiber, M.; Armstrong, W.R.; Juarez, R.; Murthy, V.; Lawhn-Heath, C.; Behr, S.C.; Zhang, L.; Barbato, F.; Ceci, F. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase 3 imaging trial. JAMA Oncol. 2021, 7, 1635–1642.
Pienta, K.J.; Gorin, M.A.; Rowe, S.P.; Carroll, P.R.; Pouliot, F.; Probst, S.; Saperstein, L.; Preston, M.A.; Alva, A.S.; Patnaik, A. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY). J. Urol. 2021, 206, 52–61.
Kirste, S.; Kroeze, S.G.; Henkenberens, C.; Schmidt-Hegemann, N.-S.; Vogel, M.M.; Becker, J.; Zamboglou, C.; Burger, I.; Derlin, T.; Bartenstein, P. Combining 68Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study. Front. Oncol. 2021, 11, 946.

© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.

Upload a video for this entry

Information

Subjects: Oncology; Urology & Nephrology; Radiology, Nuclear Medicine & Medical Imaging

Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :

Naeim Nabian

Reza Ghalehtaki

Felipe Couñago

View Times: 383

Update Date: 30 Dec 2022

Table of Contents

Video Upload Options

Confirm

1. Development of PSMA PET/CT Scan

2. Nodal Irradiation in PSMA-Positive Patients

3. Nodal Irradiation in PSMA-Negative Patients

References